Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ropivacaine + clonidine
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Epidural, Caudal, Intrathecal, Infiltration
01
Overview
A combination of ropivacaine, a local anesthetic, and clonidine, an alpha-2 adrenergic agonist. This combination is used for regional anesthesia and pain management. Ropivacaine blocks sodium channels to prevent nerve impulse generation and conduction, while clonidine potentiates the analgesic effects through a non-opioid mechanism. The combination provides enhanced and prolonged analgesia compared to ropivacaine alone, with reduced need for rescue opioid medication.
- Other names
- Ropivacain 5 mg/ml + ClonidineRopivacaine and Clonidine
02
Targets
NaV (Voltage-gated sodium channels)ADRA2A (α2A)
Beyond the preview
Go deeper on ropivacaine + clonidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ropivacaine + clonidine.